Compare · ABT vs ZGNX
ABT vs ZGNX
Side-by-side comparison of Abbott Laboratories (ABT) and Zogenix Inc. (ZGNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ZGNX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT carries a market cap of $178.38B.
- ABT has hit the wire 11 times in the past 4 weeks while ZGNX has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 6 for ZGNX).
- Company
- Abbott Laboratories
- Zogenix Inc.
- Price
- -
- -
- Market cap
- $178.38B
- -
- 1M return
- +0.63%
- -
- 1Y return
- -16.77%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2010
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 6
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Zogenix Inc.
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
Latest ABT
- Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis
- Abbott Labs upgraded by Leerink Partners with a new price target
- Abbott Laboratories filed SEC Form 8-K: Leadership Update
- New Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season
- EXECUTIVE VICE PRESIDENT Moreland Mary K sold $406,000 worth of Common shares without par value (3,500 units at $116.00), decreasing direct ownership by 3% to 100,791 units (SEC Form 4)
- SEC Form 10-Q filed by Abbott Laboratories
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
Latest ZGNX
- ReAlta Life Sciences Announces Appointment of Jonathan Rigby to Board of Directors
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
- Benzinga Pro's Top 5 Stocks To Watch For Monday, Mar. 21, 2022: BA, COIN, NILE, ZGNX, MULN
- The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings